HEMO — Hemogenyx Pharmaceuticals Share News
0.000.00%
Last trade - 00:00FDA Consents to Phase I Trials of HEMO-CAR-T
Brief: Hemogenyx Pharma Reports Approval And Issuance Of U.S. Conditioning Patent
Submission of Complete Response to Clinical Hold
Brief: Hemogenyx Pharma Announces Successful Completion Of Process Qualification Run Of End-To-End Process For Manufacture Of HEMO-CAR-T Cells
Placing to Raise £534,375
Brief: Hemogenyx Pharmaceuticals Announces Successful Completion Of Re-Manufacturing Of An Improved Lentivirus Devoid Of Splice Variants
Half-year Report
UK's Hemogenyx Pharma rises on investment from Prevail Partners
Brief: Hemogenyx Pharma Receives Investment From Prevail Partners
Brief: Hemogenyx Pharma Says Clinical Hold Lift Plan Accepted By FDA
CBR Patent Application Update
UK's Hemogenyx Pharma gains as co takes action to tackle USFDA concerns
Brief: Hemogenyx Pharma Gets USFDA Full Review Letter On INDA For Candidate Chimeric Antigen Receptor T-Cells
Posting of Annual Report & Notice of AGM
UK's Hemogenyx falls on FDA clinical hold for leukemia cancer drug
Brief: Hemogenyx Pharma Says Clinical Hold On IND For Hemo-Car-T
Brief: Hemogenyx Pharmaceuticals Announces Submission Of IND For Hemo-Car-T
Equity Incentive Pool Increase and Option Grant
Final Results for the Year Ended 31 December 2022